11th IAS Conference on HIV Science 18-21 July
2021
Virtuell
Die Tagung der Internationalen Aids Society ist traditionell wissenschaftlich ausgerichtet. Sie findet virtuell statt, es gibt jedoch einen „German Hub“ mit Präsenz in Berlin. Hier der Link zum Kongress.
HIV&more ist offizieller Media-Partner der IAS-Konferenz
HCV-Elimination: Kaum noch Hepatitis bei Menschen mit HIV in Holland
FLAIR: CAB+RPV 124 Wochen
CAB+RPV: Prädiktoren für virologisches Versagen
SALSA: Switch auf DTG/3TC
Dolutegravir vs Darunavir bei akuter HIV-Infektion
Dolutegravir/Rilpivirin bei K103
Dolutegravir kein Einfluss auf Neuralrohrdefekte
Islatravir/Doravirin zu 96 Wochen
PrEP – Cave TDF-Resistenzentwicklung
Islatravir Q1M zur PrEP
Lenacapavir als Firstline
Lenacapavir als Salvage
Tuberkulose: Neues Regime für hochresistente Tuberkulose
HIV: Immunmodulation zur funktionellen Heilung
COVID-19: HIV ist ein Risikofaktor für schweren Verlauf
IAS2021 Publikationen Gilead Sciences
Epting-M_HIV-testing-strategies-in-jails_IAS-2021_PED435.pdf
Greenberg-L_INSTI-use-and-cancer-incidence_IAS-2021_PEB143.pdf
Liu-G_HPV-increases-HIV-risk-in-African-women_IAS-2021_OAC0404.pdf
Maggiolo-F_BFTAF-switch-trial-4449-in-PLWH-65-and-older-at-Wk96_IAS-2021_PEB160-Poster.pptx
Parkin-N_Definition-of-counter-factual-HIV-infection-rate-for-new-PrEP-trials_IAS-2021_PEC307.pptx
Sacks-NC_Adherence-to-PrEP-with-FTAF-or-FTDF-from-claims-database-in-the-US_IAS-2021_OAC0103.pptx
Spinner-C_FTAF-for-PrEP-in-DISCOVER-at-OLE-phase-Wk48_IAS-2021_OALC0501.pptx
Tao-L_PrEP-utilization-during-COVID-19-in-the-US_IAS-2021_OAC0203.pptx
Wright-E_Lower-HIV-reservoirs-in-individuals-with-higher-CD4-prior-ART-in-START_IAS-2021_PEBLB13.pdf
IAS 2021 Publikationen ViiV
| DOLUTEGRAVIR | |
|---|---|
| Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA) J M Llibre Oral Presentation |
View
Abstract View Presentation Download Presentation |
| Comparison of Viral Replication for the 2-Drug Regimen (2DR) of Dolutegravir/Lamivudine (DTG/3TC) versus a 3/4-Drug Tenofovir Alafenamide-based regimen (TBR) in the TANGO Study through Week 96 R Wang On-Demand Oral Abstract Presentation |
View
Abstract View Presentation Download Presentation |
| Metabolic health outcomes at week 96 in the TANGO Study, comparing a switch to DTG/3TC versus maintenance of TAF-based regimens J van Wyk E-Poster |
View
Abstract View Presentation Download Presentation |
| Feasibility, Efficacy, and Safety of Dolutegravir/Lamivudine (DTG/3TC) as a First-line Regimen in a Test-and-Treat Setting for Newly Diagnosed People Living With HIV (PLWH): 48-Week Results of the STAT Study C Rolle E-Poster |
View
Abstract View Presentation Download Presentation |
| DTG+3TC in GEMINI-1&-2: HIV-1 replication at <50 c/mL and VL blips through 144 weeks M Underwood E-Poster |
View
Abstract View Presentation Download Presentation |
| Integrase strand transfer inhibitor (INSTI) use and cancer incidence L Greenberg, on behalf of the RESPOND study group E-Poster |
View
Abstract Download Presentation |
| CABOTEGRAVIR+RILPIVIRINE-Long-Acting for Treatment | |
| Week 124 results of the randomized, open-label, phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) C Orkin On-Demand Oral Abstract Presentation |
View
Abstract View Presentation Download Presentation |
| CUSTOMIZE: Overall results from a hybrid III implementation-effectiveness study examining implementation of cabotegravir and rilpivirine long-acting injectable (CAB+RPV LA) for HIV treatment in US healthcare settings; final patient and provider data M Czarnogorski On-Demand Oral Abstract Presentation |
View
Abstract View Presentation Download Presentation |
| CAB+RPV LA implementation outcomes and acceptability of monthly clinic visits improved during COVID-19 pandemic across US healthcare clinics (CUSTOMIZE: Hybrid III Implementation-Effectiveness Study) M Czarnogorski E-Poster |
View
Abstract View Presentation Download Presentation |
| Clinical outcomes during CUSTOMIZE: a hybrid III implementation-effectiveness study focused on implementation of cabotegravir plus rilpivirine (CAB+RPV) LA in US healthcare settings G Sinclair E-Poster |
View
Abstract View Presentation Download Presentation |
| CABOTEGRAVIR Long-Acting for PrEP | |
| High interest in long-acting injectable HIV pre-exposure prophylaxis among nationwide sample of men who have sex with men in the US: AMIS 2019 T Sanchez E-Poster |
View
Abstract Download Presentation |
| Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP M Moore On-Demand Oral Abstract Presentation | View Abstract |
| Understanding participant experiences and preferences in an injectable PrEP trial: a qualitative sub-study of barriers, facilitators, and preferences for PrEP use among MSM and TGW C Psaros Oral Presentation | View Abstract |
| Long-acting Injectable PrEP in Women: laboratory analysis of HIV Infections in HPTN 084. S Delany-Moretlwe E-Poster | View Abstract |
| Preferences for Implementing Long-Acting Injectable Pre-Exposure Prophylaxis among Cisgender Men Who have Sex with Men in the US S Wilson Beckham Oral Presentation |
View
Abstract View Presentation Download Presentation |
| Variation in preferences for long-acting injectable PrEP among US men who have sex with men: A latent class analysis S Wilson Beckham On-Demand Oral Abstract Presentation |
View
Abstract View Presentation Download Presentation |
| FOSTEMSAVIR | |
| Antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analyses of the phase 3 BRIGHTE study P Ackerman E-Poster |
View
Abstract View Presentation Download Presentation |
| Long-term (96 week) safety of fostemsavir (FTR) in heavily-treatment experienced (HTE) adults infected with multi-drug resistance (MDR) HIV-1 (BRIGHTE phase 3 study) B Shepherd E-Poster |
View
Abstract View Presentation Download Presentation |
Kollegen Fragen
Diese Seite weiter empfehlen
